Have a feature idea you'd love to see implemented?
Let us know!
RZLT Rezolute Inc
Price (delayed)
$4.86
Market cap
$281.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.27
Enterprise value
$273.21M
Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric
Highlights
RZLT's debt is down by 11% year-on-year and by 7% since the previous quarter
Rezolute's quick ratio has increased by 2.6% from the previous quarter
Rezolute's EPS has decreased by 17% YoY but it has increased by 4.5% QoQ
Rezolute's equity has increased by 10% YoY but it has decreased by 6% QoQ
Rezolute's net income has decreased by 23% YoY
Key stats
What are the main financial stats of RZLT
Market
Valuations
Earnings
Shares outstanding
57.94M
Market cap
$281.6M
Enterprise value
$273.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$69.31M
EBITDA
-$68.75M
Free cash flow
-$62.8M
Per share
Balance sheet
Liquidity
EPS
-$1.27
Free cash flow per share
-$0.9
Book value per share
$2.05
Revenue per share
$0
TBVPS
$1.77
Total assets
$123.41M
Total liabilities
$9.97M
Debt
$2.08M
Equity
$113.44M
Working capital
$102.19M
Debt to equity
0.02
Current ratio
13.79
Quick ratio
13.55
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-62.2%
Return on equity
-69.8%
Return on invested capital
-85.7%
Return on capital employed
-60.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RZLT stock price
How has the Rezolute stock price performed over time
Intraday
-2.99%
1 week
-13.21%
1 month
-0.61%
1 year
504.18%
YTD
389.67%
QTD
0.21%
Financial performance
How have Rezolute's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.45M
Net income
-$69.31M
Gross margin
N/A
Net margin
N/A
Rezolute's net income has decreased by 23% YoY
Rezolute's operating income has decreased by 16% YoY
Growth
What is Rezolute's growth rate over time
Valuation
What is Rezolute stock price valuation
P/E
N/A
P/B
2.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rezolute's EPS has decreased by 17% YoY but it has increased by 4.5% QoQ
The stock's price to book (P/B) is 69% more than its last 4 quarters average of 1.4 and 58% more than its 5-year quarterly average of 1.5
Rezolute's equity has increased by 10% YoY but it has decreased by 6% QoQ
Efficiency
How efficient is Rezolute business performance
The ROE has dropped by 51% year-on-year
RZLT's return on assets is down by 43% year-on-year
The company's return on invested capital fell by 15% YoY
Dividends
What is RZLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RZLT.
Financial health
How did Rezolute financials performed over time
The total liabilities is down by 15% QoQ but it is up by 6% YoY
RZLT's total assets is up by 9% year-on-year but it is down by 7% since the previous quarter
RZLT's debt is 98% smaller than its equity
RZLT's debt is down by 11% year-on-year and by 7% since the previous quarter
Rezolute's equity has increased by 10% YoY but it has decreased by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.